PBAC's latest decision on Imatinib: Recommended (2021). Considered for Listing of imatinib 600 mg tablets under the same circumstances as existing PBS-listed imatinib 100 mg and 400 mg tablets for multiple indications including chronic myeloid leukaemia, Philadelphia chromosome-positive acute lymphoblastic leukaemia, and other haematologic and solid malignancies.
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
7
first 2010
Submissions
7
2010 → 2021
Eligible population
Patients with chronic myeloid leukaemia, Philadelphia chromosome-positive acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, chronic eosinophilic leukaemia, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumours requiring imatinib therapy at doses up to 600 mg daily.
Therapy area
Haematology
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
imatinib 100 mg and 400 mg tablets
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated by design.
ICER (historical)
$45k/QALY–$75k/QALY across 4 submissions (2010–2012) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Submission history
Jul 2010: Not recommended · Authority Required — ICER $75k/QALY
Mar 2011: Recommended · Authority Required — ICER $45k/QALY
Mar 2012: Not recommended — ICER $75k/QALY
Nov 2012: Recommended with restriction · Authority Required — ICER $75k/QALY
Mar 2015: Not recommended · Not applicable
Jul 2018: Recommended with restriction · Authority Required